Insmed Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Insmed stock.
View analyst ratings for Insmed or view top-rated stocks.

Wall Street analysts have given Insmed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Insmed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Insmed.

Insmed will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "984249".

Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.91) by $0.02. The biopharmaceutical company had revenue of $40.21 million for the quarter, compared to analysts' expectations of $41.64 million. Insmed had a negative net margin of 190.36% and a negative trailing twelve-month return on equity of 103.03%. Insmed's quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm earned ($0.74) earnings per share.
View Insmed's earnings history.

Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INSM shares have increased by 15.8% and is now trading at $24.60.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued 12 month price targets for Insmed's shares. Their forecasts range from $44.00 to $60.00. On average, they anticipate Insmed's share price to reach $53.83 in the next twelve months. This suggests a possible upside of 118.8% from the stock's current price.
View analysts' price targets for Insmed or view top-rated stocks among Wall Street analysts.

14 employees have rated Insmed CEO Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among Insmed's employees.

Some companies that are related to Insmed include Jazz Pharmaceuticals (JAZZ), CureVac (CVAC), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), I-Mab (IMAB), Sarepta Therapeutics (SRPT) and Ultragenyx Pharmaceutical (RARE).
View all of INSM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.98%), Scout Investments Inc. (0.33%), Rice Hall James & Associates LLC (0.29%), Oak Ridge Investments LLC (0.08%) and Harbor Investment Advisory LLC (0.00%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, John Goll, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer and William Lewis.
View institutional ownership trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, and Oak Ridge Investments LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Christine A Pellizzari, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer, and William Lewis.
View insider buying and selling activity for Insmed or view top insider-selling stocks.

INSM stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Scout Investments Inc., and Harbor Investment Advisory LLC.
View insider buying and selling activity for Insmed or or view top insider-buying stocks.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INSM stock can currently be purchased for approximately $24.60.

Insmed has a market capitalization of $2.55 billion and generates $164.41 million in revenue each year. The biopharmaceutical company earns $-294,090,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis.

Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed is headquartered at 700 US Highway 202/206, Bridgewater NJ, 08807.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]